Ryan Edward Brown Sarepta Therapeutics, Inc. (SRPT) insider trading activity

Ryan Edward Brown is EVP, General Counsel of Sarepta Therapeutics, Inc.. Currently has a direct ownership of 17,129 shares of SRPT, which is worth approximately $2.21 Million. The most recent transaction as insider was on Jun 25, 2024, when has been sold 38,957 shares (Common Stock) at a price of $161.43 per share, resulting in proceeds of $6,288,828. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 17.1K

40.29% 3M change

39.03% 12M change

Total Value Held $2.21 Million

Ryan Edward Brown Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 25 2024	SELL Open market or private sale	$6,288,828 $161.43 p/Share	38,957 Reduced 69.46%	17,129 Common Stock
Jun 25 2024	BUY Exercise of conversion of derivative security	$1,475,095 $62.77 p/Share	23,500 Added 29.53%	56,086 Common Stock
Jun 24 2024	SELL Payment of exercise price or tax liability	$387,233 $164.64 p/Share	2,352 Reduced 6.73%	32,586 Common Stock
Jun 21 2024	BUY Exercise of conversion of derivative security	-	6,250 Added 15.17%	34,938 Common Stock
Mar 08 2024	SELL Payment of exercise price or tax liability	$110,702 $123.14 p/Share	899 Reduced 3.04%	28,688 Common Stock
Mar 07 2024	SELL Payment of exercise price or tax liability	$60,967 $120.49 p/Share	506 Reduced 1.68%	29,587 Common Stock
Mar 04 2024	SELL Payment of exercise price or tax liability	$217,304 $125.32 p/Share	1,734 Reduced 5.45%	30,093 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$33,945 $126.19 p/Share	269 Reduced 0.96%	27,827 Common Stock
Mar 01 2024	SELL Open market or private sale	$250,680 $125.34 p/Share	2,000 Reduced 5.91%	31,827 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	6,000 Added 15.07%	33,827 Common Stock
Jun 01 2023	SELL Payment of exercise price or tax liability	$11,000 $123.6 p/Share	89 Reduced 0.32%	28,096 Common Stock
Mar 08 2023	SELL Payment of exercise price or tax liability	$97,275 $153.19 p/Share	635 Reduced 2.2%	28,185 Common Stock
Mar 06 2023	SELL Payment of exercise price or tax liability	$208,303 $157.21 p/Share	1,325 Reduced 5.17%	24,320 Common Stock
Mar 06 2023	BUY Grant, award, or other acquisition	-	4,500 Added 13.51%	28,820 Common Stock
Mar 01 2023	SELL Payment of exercise price or tax liability	$28,923 $147.57 p/Share	196 Reduced 0.76%	25,645 Common Stock
Jun 01 2022	SELL Payment of exercise price or tax liability	$3,924 $72.67 p/Share	54 Reduced 0.21%	25,841 Common Stock
Mar 07 2022	SELL Payment of exercise price or tax liability	$12,142 $79.36 p/Share	153 Reduced 0.85%	17,895 Common Stock
Mar 07 2022	BUY Grant, award, or other acquisition	-	8,000 Added 23.6%	25,895 Common Stock
Mar 04 2022	SELL Payment of exercise price or tax liability	$89,971 $79.2 p/Share	1,136 Reduced 5.92%	18,048 Common Stock
Mar 01 2022	SELL Payment of exercise price or tax liability	$13,809 $75.05 p/Share	184 Reduced 0.95%	19,184 Common Stock
Jun 01 2021	SELL Payment of exercise price or tax liability	$4,865 $76.01 p/Share	64 Reduced 0.33%	19,368 Common Stock
Mar 03 2021	BUY Grant, award, or other acquisition	-	15,000 Added 43.06%	19,838 Common Stock

REB

Ryan Edward Brown

EVP, General Counsel

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SRPT shares.

Notify only if

Value

Insider Trading

Get notified when an Sarepta Therapeutics, Inc. insider buys or sells SRPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Sarepta Therapeutics, Inc.

Track Activities on SRPT

Account